FibroGen CEO Enrique Conterno (Duke University Fuqua School of Business via YouTube)

SEC jumps in­to the Fi­bro­Gen fi­as­co with a sub­poe­na, prob­ing car­dio da­ta ma­nip­u­la­tion

As­traZeneca part­ner Fi­bro­Gen stunned an­a­lysts last April with the news that the safe­ty da­ta around their ane­mia drug rox­adu­s­tat had been doc­tored up to make cer­tain safe­ty is­sues dis­ap­pear. And now we know that the SEC has de­cid­ed to get in­to the act.

From their 10-K yes­ter­day:

In the fourth quar­ter of 2021, Fi­bro­Gen re­ceived a sub­poe­na from the SEC re­quest­ing doc­u­ments re­lat­ed to rox­adu­s­tat’s pooled car­dio­vas­cu­lar safe­ty da­ta. We have been ful­ly co­op­er­at­ing with the SEC’s in­ves­ti­ga­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.